van Gorp Pim R R, Trines Serge A, Pijnappels Daniël A, de Vries Antoine A F
Laboratory of Experimental Cardiology, Department of Cardiology, Leiden University Medical Center, Leiden, Netherlands.
Front Cardiovasc Med. 2020 Mar 31;7:43. doi: 10.3389/fcvm.2020.00043. eCollection 2020.
Atrial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice with a large socioeconomic impact due to its associated morbidity, mortality, reduction in quality of life and health care costs. Currently, antiarrhythmic drug therapy is the first line of treatment for most symptomatic AF patients, despite its limited efficacy, the risk of inducing potentially life-threating ventricular tachyarrhythmias as well as other side effects. Alternative, in-hospital treatment modalities consisting of electrical cardioversion and invasive catheter ablation improve patients' symptoms, but often have to be repeated and are still associated with serious complications and only suitable for specific subgroups of AF patients. The development and progression of AF generally results from the interplay of multiple disease pathways and is accompanied by structural and functional (e.g., electrical) tissue remodeling. Rational development of novel treatment modalities for AF, with its many different etiologies, requires a comprehensive insight into the complex pathophysiological mechanisms. Monolayers of atrial cells represent a simplified surrogate of atrial tissue well-suited to investigate atrial arrhythmia mechanisms, since they can easily be used in a standardized, systematic and controllable manner to study the role of specific pathways and processes in the genesis, perpetuation and termination of atrial arrhythmias. In this review, we provide an overview of the currently available two- and three-dimensional multicellular systems for investigating the initiation, maintenance and termination of atrial arrhythmias and AF. This encompasses cultures of primary (animal-derived) atrial cardiomyocytes (CMs), pluripotent stem cell-derived atrial-like CMs and (conditionally) immortalized atrial CMs. The strengths and weaknesses of each of these model systems for studying atrial arrhythmias will be discussed as well as their implications for future studies.
心房颤动(AF)是临床实践中最常见的心律失常,由于其相关的发病率、死亡率、生活质量下降和医疗保健成本,具有巨大的社会经济影响。目前,抗心律失常药物治疗是大多数有症状AF患者的一线治疗方法,尽管其疗效有限,存在诱发潜在危及生命的室性快速性心律失常的风险以及其他副作用。作为替代方案,包括电复律和侵入性导管消融在内的院内治疗方式可改善患者症状,但通常需要重复进行,且仍伴有严重并发症,仅适用于特定亚组的AF患者。AF的发生和进展通常是多种疾病途径相互作用的结果,并伴有结构和功能(如电)组织重塑。针对病因多样的AF合理开发新型治疗方式,需要全面深入了解复杂的病理生理机制。心房细胞单层代表了心房组织的一种简化替代物,非常适合研究房性心律失常机制,因为它们可以很容易地以标准化、系统化和可控的方式用于研究特定途径和过程在房性心律失常的发生、持续和终止中的作用。在本综述中,我们概述了目前可用于研究房性心律失常和AF的起始、维持及终止的二维和三维多细胞系统。这包括原代(动物来源)心房心肌细胞(CMs)、多能干细胞衍生的心房样CMs和(条件性)永生化心房CMs的培养。将讨论每种这些模型系统在研究房性心律失常方面的优缺点及其对未来研究的意义。